Compare BLBD & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BLBD | AGIO |
|---|---|---|
| Founded | 1927 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Construction/Ag Equipment/Trucks | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.6B |
| IPO Year | 2013 | 2013 |
| Metric | BLBD | AGIO |
|---|---|---|
| Price | $53.38 | $27.85 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 8 |
| Target Price | ★ $67.20 | $37.63 |
| AVG Volume (30 Days) | 392.7K | ★ 708.3K |
| Earning Date | 05-11-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 22.78 | N/A |
| EPS | ★ 0.94 | N/A |
| Revenue | ★ $1,480,099,000.00 | $43,011,000.00 |
| Revenue This Year | $6.07 | $75.68 |
| Revenue Next Year | $6.37 | $167.63 |
| P/E Ratio | $56.91 | ★ N/A |
| Revenue Growth | ★ 9.87 | N/A |
| 52 Week Low | $30.15 | $22.24 |
| 52 Week High | $62.90 | $46.00 |
| Indicator | BLBD | AGIO |
|---|---|---|
| Relative Strength Index (RSI) | 40.99 | 46.37 |
| Support Level | $49.55 | $26.48 |
| Resistance Level | $58.25 | $29.49 |
| Average True Range (ATR) | 2.03 | 1.13 |
| MACD | -0.95 | -0.17 |
| Stochastic Oscillator | 10.05 | 25.09 |
Blue Bird Corp is an American bus manufacturing company. It is an independent designer and manufacturer of school buses. The company operates in two segments; the Bus segment which involves the design, engineering, manufacture, and sales of school buses and extended warranties; and the Parts segment which includes the sales of replacement bus parts. Geographically, the company generates a majority of its revenue from its customers in the United States and the rest from Canada and Rest of the world.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.